Ahmedabad : Torrent Pharmaceuticals Limited (‘’Company”) today announced its financial results for the first quarter of FY 26.
Revenue & profitability:
- Revenue at Rs. 3,178 crores; grew by 11% YoY
- EBITDA at Rs.1,032* crores, up by 14% YoY
- EBITDA margin at 32.5%; Gross Margin: 76%
- *Includes acquisition related one-off expenses of Rs. 15 crores. Op. EBITDA adjusted for these one-offs is 1,047 crores, with a margin of 32.9%
- Net Profit after tax at Rs. 548 crores, up by 20% YoY.
Performance summary:
| Results | Q1 FY26 | Q1 FY25 | YoY% | ||
| Rs cr | % | Rs cr | % | ||
| Revenues | 3,178 | 2,859 | 11% | ||
| Gross profit | 2,404 | 76% | 2,165 | 76% | 11% |
| Op EBITDA | 1,032 | 32% | 904 | 32% | 14% |
| PAT | 548 | 17% | 457 | 16% | 20% |
| R&D spend | 157 | 5% | 135 | 5% | 16% |
India:
- India revenues at Rs 1,811 crores were up by 11% led by outperformance in focus therapies.
- As per AIOCD secondary market data, IPM growth for the quarter was 8%.
- Torrent’s chronic business grew at 13% vs IPM growth of 9%
- Torrent has 21 brands in the Top 500 brands in IPM, with 14 brands having more than Rs.100 crores sales.
Brazil:
- Brazil revenues at Rs 218 crores, were up by 11%.
- Constant currency revenues at R$ 143 million, were up by 16%.
- As per IQVIA, Torrent grew at 14% vs market growth of 5%.
- Growth was aided by the performance of top brands & new launches.
- Torrent has 62 products under ANVISA review.
Germany:
- Germany revenues at Rs 308 crores, were up by 9%.
- Constant currency revenues at EUR 32 million, were up by 1%.
- Growth was impacted due to supply disruption at third party supplier.
United States:
- US business revenues at Rs 308 crores, were up by 19%.
- Constant currency revenues at $36 million, were up by 16% compared to same period in the previous year. Recent launches have achieved targeted market shares.